ArticlemAbs2026

Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safety.

Matthew Siegel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.